Department of Medical and Clinical Biophysics, Faculty of Medicine, University of Pavol Jozef Šafárik in Košice, Trieda SNP 1, 04011 Košice, Slovakia.
Center of Clinical and Preclinical Research MEDIPARK, Faculty of Medicine, University of Pavol Jozef Šafárik in Košice, Trieda SNP 1, 04011 Košice, Slovakia.
Int J Mol Sci. 2024 Jul 4;25(13):7351. doi: 10.3390/ijms25137351.
Despite advances in the genomic classification of breast cancer, current clinical tests and treatment decisions are commonly based on protein-level information. Nowadays breast cancer clinical treatment selection is based on the immunohistochemical (IHC) determination of four protein biomarkers: Estrogen Receptor 1 (ESR1), Progesterone Receptor (PGR), Human Epidermal Growth Factor Receptor 2 (HER2), and proliferation marker Ki-67. The prognostic correlation of tumor-infiltrating T cells has been widely studied in breast cancer, but tumor-infiltrating B cells have not received so much attention. We aimed to find a correlation between immunohistochemical results and a proteomic approach in measuring the expression of proteins isolated from B-cell lymphocytes in peripheral blood samples. Shotgun proteomic analysis was chosen for its key advantage over other proteomic methods, which is its comprehensive and untargeted approach to analyzing proteins. This approach facilitates better characterization of disease-associated changes at the protein level. We identified 18 proteins in B cell lymphocytes with a significant fold change of more than 2, which have promising potential to serve as breast cancer biomarkers in the future.
尽管在乳腺癌的基因组分类方面取得了进展，但目前的临床检测和治疗决策通常基于蛋白质水平的信息。如今，乳腺癌的临床治疗选择是基于对四种蛋白质生物标志物的免疫组织化学（IHC）测定：雌激素受体 1（ESR1）、孕激素受体（PGR）、人表皮生长因子受体 2（HER2）和增殖标志物 Ki-67。肿瘤浸润 T 细胞的预后相关性已在乳腺癌中广泛研究，但肿瘤浸润 B 细胞尚未受到太多关注。我们旨在寻找免疫组织化学结果与从外周血样本中的 B 细胞淋巴细胞中分离的蛋白质的蛋白质组学方法之间的相关性。我们选择了 shotgun 蛋白质组学分析，因为它相对于其他蛋白质组学方法具有关键优势，即其对蛋白质进行全面和非靶向分析的方法。这种方法有助于更好地在蛋白质水平上描述与疾病相关的变化。我们在 B 细胞淋巴细胞中鉴定出 18 种具有超过 2 倍折叠变化的蛋白质，它们具有成为未来乳腺癌生物标志物的巨大潜力。
